We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ:DYN) stands against the other NASDAQ stocks.
Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he sees investing opportunities following Trump’s election. He believes investing in the tech sector makes the most sense given the implications of the 2024 election results for the financial markets. He noted that the election has shifted the underlying dynamics affecting businesses, particularly regarding regulation and taxation. The new administration has changed the previous climate of heightened regulation and discussions around increasing capital gains and corporate taxes. Avallone believes that the potential for reduced regulation and lower taxes on corporations could create a more favorable environment for business growth.
He emphasized that corporate America’s ability to deliver earnings will be crucial, relying on continued efficiencies and advancements in technology. This perspective supports his thesis that investing in technology remains a sound strategy for investors. When discussing specific stocks, Avallone highlighted major tech companies from the MAG7 as particularly attractive. He expressed confidence that the current administration would foster a more supportive environment for these companies, allowing them to thrive.
Avallone also touched on the defense sector, which has historically benefited from global conflicts. He pointed out that defense companies have shown resilience and believes that ongoing global tensions will sustain demand for defense stocks, providing a hedge against market volatility.
However, Avallone expressed caution regarding the healthcare sector, which has been lagging due to heavy regulation and political scrutiny. He noted that despite an aging population driving demand for medical equipment, regulatory pressures have hindered growth in this area. Overall, his analysis underscores a cautious optimism about investing in technology and defense while highlighting potential challenges within healthcare as businesses navigate the post-election landscape.
Methodology
We sifted through Finviz to compile a list of 30 NASDAQ stocks with high upside potentials. We then selected the 12 stocks with the biggest upside potential according to analysts. The stocks are ranked in ascending order of their analysts’ upside potential.
A lab technician working with chemicals and equipment to create a novel therapeutic drug.
Dyne Therapeutics Inc. (NASDAQ:DYN)
Average Upside Potential as of November 21: 73.44%
Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people with genetically driven diseases. Its primary focus is on myotonic dystrophy type 1 (DM1), and Duchenne muscular dystrophy (DMD), among other rare diseases.
A significant milestone for the company was the FDA’s clearance of the IND application for DYNE-101, a drug designed to treat DM1. The drug is being evaluated in the ongoing Phase 1/2 ACHIEVE trial for adults with DM1. New data from this trial, including safety, efficacy, and patient-reported outcomes, is expected in early January 2025. This data will inform the go-forward dose and regimen for DYNE-101.
In parallel, the company is also advancing its DYNE-251 program for Duchenne muscular dystrophy (DMD). Positive results from the Phase 1/2 DELIVER trial have led to the start of a new study to test a specific dosage of DYNE-251 (20 mg/kg every 4 weeks). The company is aiming for faster approval processes for both DYNE-101 and DYNE-251.
Despite challenges, with positive clinical data and regulatory approvals, the company is well-positioned to bring innovative therapies to patients with significant unmet needs.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
